Interim Statement Q3/2022
INTERIM STATEMENT FOR JANUARY-
|
Contents |
|
|
Summary.......................................................................................................................................................................................... |
|
|
Third quarter in brief .................................................................................................................................................................. |
6 |
|
Group CEO's comment............................................................................................................................................................... |
7 |
|
Outlook............................................................................................................................................................................................. |
8 |
|
Outlook for 2022........................................................................................................................................................................... |
8 |
|
The major risks and uncertainties for the Group in thenear-term.............................................................................. |
8 |
|
Business areas ............................................................................................................................................................................... |
9 |
|
If .......................................................................................................................................................................................................... |
9 |
|
|
13 |
|
Hastings............................................................................................................................................................................................ |
14 |
|
Mandatum........................................................................................................................................................................................ |
15 |
|
Holding.............................................................................................................................................................................................. |
16 |
|
Other developments ................................................................................................................................................................... |
17 |
|
Exit from Nordea........................................................................................................................................................................... |
17 |
|
Group solvency.............................................................................................................................................................................. |
17 |
|
Financial leverage position........................................................................................................................................................ |
17 |
|
Ratings.............................................................................................................................................................................................. |
18 |
|
Shares and shareholders ............................................................................................................................................................ |
18 |
|
Effects of external events on |
19 |
|
Remuneration................................................................................................................................................................................. |
19 |
|
Personnel ......................................................................................................................................................................................... |
20 |
|
Events after the end of the reporting period...................................................................................................................... |
20 |
|
Tables................................................................................................................................................................................................ |
22 |
|
Group financial review................................................................................................................................................................. |
22 |
|
Calculation of key figures........................................................................................................................................................... |
24 |
|
Group quarterly comprehensive income statement......................................................................................................... |
26 |
|
Statement of profit and other comprehensive income ................................................................................................... |
27 |
|
Consolidated balance sheet ...................................................................................................................................................... |
28 |
|
Statement of changes in equity............................................................................................................................................... |
29 |
|
Statement of cash flows ............................................................................................................................................................. |
30 |
|
Notes ................................................................................................................................................................................................. |
31 |
|
Accounting policies...................................................................................................................................................................... |
31 |
|
Comprehensive income statement by segment for nine months ended |
33 |
|
Comprehensive income statement by segment for nine months ended |
34 |
|
Consolidated balance sheet by segment at |
35 |
|
Consolidated balance sheet by segment at |
36 |
|
Other notes..................................................................................................................................................................................... |
37 |
|
1 Insurance premiums written................................................................................................................................................... |
37 |
|
2 Net income from investments............................................................................................................................................... |
38 |
|
3 Other operating income.......................................................................................................................................................... |
39 |
|
4 Financial assets .......................................................................................................................................................................... |
39 |
|
5 Liabilities for insurance and investment contracts........................................................................................................ |
40 |
|
6 Financial liabilities ..................................................................................................................................................................... |
40 |
|
7Non-currentassets held for sale ......................................................................................................................................... |
41 |
|
8 Subsequent events after the balance sheet date .......................................................................................................... |
42 |
2
INTERIM STATEMENT FOR JANUARY-
January-
- Group P&C gross written premiums increased by 7 per cent year-on-year.
Strong Group combined ratio of 81.6 percent (80.9) .- Underwriting profit increased by 3 per cent to
EUR 1,009 million (985). Excluding COVID-19 effects reported in the 2021 comparison period, underwriting profit grew 13 per cent. - Profit before taxes amounted to
EUR 1,472 million (1,974) and earnings per share toEUR 2.19 (2.74). Excluding all Nordea-related items, profit before taxes wasEUR 1,212 million (1,356). - Group Solvency II coverage including dividend accrual increased to 238 per cent from 185 per cent at the 2021 year-end and 233 per cent at the end of the second quarter.
Key figures
|
EURm |
1-9/2022 |
1-9/2021 |
Change, % |
7-9/2022 |
7-9/2021 |
Change, % |
|
Profit before taxes |
1,472 |
1,974 |
-25 |
407 |
632 |
-36 |
|
If |
932 |
818 |
14 |
270 |
252 |
7 |
|
|
92 |
256 |
-64 |
32 |
48 |
-33 |
|
Hastings |
65 |
115 |
-43 |
40 |
31 |
30 |
|
Mandatum |
189 |
201 |
-6 |
74 |
59 |
24 |
|
Holding |
194 |
584 |
-67 |
-10 |
242 |
- |
|
Profit for the period |
1,218 |
1,662 |
-27 |
321 |
550 |
-42 |
|
Underwriting profit |
1,009 |
985 |
3 |
330 |
327 |
1 |
|
Change |
Change |
|||||
|
Earnings per share, EUR |
2.19 |
2.74 |
-0.55 |
0.58 |
0.93 |
-0.35 |
|
EPS (without eo. items), EUR *) |
2.00 |
2.31 |
-0.31 |
0.58 |
0.67 |
-0.09 |
|
EPS (including OCI), EUR **) |
-0.97 |
3.67 |
-4.64 |
-0.28 |
1.01 |
-1.63 |
|
RoE (including OCI), % |
-6.3 |
22.7 |
-29.0 |
- |
- |
- |
*) Nordea-related accounting effects of
**) OCI refers to Other comprehensive income.
The figures in this report have not been audited.
|
Target |
1-9/2022 |
|
|
Mid-single digit |
3% (13% excluding reported COVID-19 effects in |
|
|
average (excluding COVID-19 effects) |
1-9/2021) |
|
|
Group |
||
|
Group combined ratio: below 86% |
81.6% |
|
|
Solvency ratio: 170-190% |
256% (238% including dividend accrual) |
|
|
Financial leverage: below 30% |
25.9% |
|
|
If |
Combined ratio: below 85% |
79.8% |
|
Hastings |
Operating ratio: below 88% |
88.0% |
|
Loss ratio: below 76% |
77.6% |
|
Financial targets for 2021-2023 announced at the Capital Markets Day on
January-
3
INTERIM STATEMENT FOR JANUARY-
SUMMARY
Financial highlights for January-
If P&C reported robust results for January-
Hastings delivered solid performance in a challenging
The Mandatum segment's profit before taxes for January-
The Holding segment's profit before taxes amounted to
4
INTERIM STATEMENT FOR JANUARY-
SUMMARY
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Disclaimer



Enrollment for subsidized health insurance begins Nov. 1 on Kynect
Commentary: The health of our nation’s health care system is under attack
Advisor News
- How smart investments prepare clients for inflation
- Amid slew of corporate tax ideas, Newsom chose one likely to hit people’s premiums
- The biggest risk to your clients’ financial plans isn’t market volatility
- Initiative looks at how caregiving impacts workplace benefits
- Will rising retirement needs spark an annuity boom?
More Advisor NewsAnnuity News
- Globe Life Inc. (NYSE: GL) Records 52-Week High Thursday Morning
- Fortitude Re Completes $500 Million FABN Issuance
- Reframing retirement income for greater certainty
- Jackson Introduces Dow Jones Industrial Average Index Option, Flexible Premiums, Six-Year Rate Guarantee in Latest Registered Index-Linked Annuity Launch
- Senior Market Sales® Fortifies Annuity Reach With Acquisition of Retirement Planning Firm Stratton & Company
More Annuity NewsHealth/Employee Benefits News
- As Affordable Care Act premiums skyrocket, catastrophic coverage is having a moment (copy)
- Report Summarizes Geriatrics and Gerontology Study Findings from National Center for Geriatrics and Gerontology (Multi-domain Functional Dispersion and Disability-Free Survival among Community-Dwelling Older Adults: An Exploratory Study): Aging Research – Geriatrics and Gerontology
- Findings from Brown University in Managed Care Reported (Third-Party Convener Firms And The Rise Of Geographically Dispersed, High-Earning Medicare ACOs): Managed Care
- Findings from Arnot Ogden Medical Center Broaden Understanding of Diabetic Ketoacidosis (Diabetic Ketoacidosis From Health Insurance-Requested Non-medical Switching): Nutritional and Metabolic Diseases and Conditions – Diabetic Ketoacidosis
- Mark Farrah Associates Analyzed the 2025 Medicare Supplement Market
More Health/Employee Benefits NewsLife Insurance News
- Lobbyist argues Iowa insurance regulator gives too much voice to Wall Street
- Appeals court rejects investor payouts in latest decision against STOLI
- Why premium-financed IUL is failing
- AM Best Affirms Issue Credit Ratings of Weston2038 LLC’s Credit-Linked Notes
- Globe Life Inc. (NYSE: GL) Records 52-Week High Thursday Morning
More Life Insurance News